Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Rini

Showing results (101-110 of 401) with videos related to

Pageof 41
Sort By:
JAMA Oncology|September 8, 2018
Information Transparency in the Drug Approval ProcessBrian I Rini, Harold J Burstein, Daniel J George
Current Urology Reports|January 1, 2009
Integration of surgery and systemic therapy in the management of metastatic renal cancerAnil A Thomas, Brian I Rini, Steven C Campbell
Current Opinion in Oncology|April 9, 2005
Renal cell carcinomaW Kimryn Rathmell, Paul A Godley, Brian I Rini
Expert Review of Anticancer Therapy|December 13, 2005
Molecularly targeted therapy in renal cell carcinomaW Kimryn Rathmell, Tricia M Wright, Brian I Rini
Expert Review of Anticancer Therapy|December 9, 2016
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?Frede Donskov, Daniel Y C Heng, Brian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Clinical Pharmacokinetics|May 8, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorReza Khosravan, Robert J Motzer, Elena Fumagalli, et al.
Clinical Prostate Cancer|July 5, 2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancerGarth Beinart, Brian I Rini, Vivian Weinberg, et al.
Case Reports in Oncological Medicine|November 10, 2015
Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?Bo Zhao, Laura S Wood, Karen James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerBrian I Rini, Vivian Weinberg, Robert Bok, et al.
Pageof 41

Showing results (101-110 of 401) with videos related to

Sort By:
Pageof 41
JAMA Oncology|September 8, 2018
Information Transparency in the Drug Approval ProcessBrian I Rini, Harold J Burstein, Daniel J George
Current Urology Reports|January 1, 2009
Integration of surgery and systemic therapy in the management of metastatic renal cancerAnil A Thomas, Brian I Rini, Steven C Campbell
Current Opinion in Oncology|April 9, 2005
Renal cell carcinomaW Kimryn Rathmell, Paul A Godley, Brian I Rini
Expert Review of Anticancer Therapy|December 13, 2005
Molecularly targeted therapy in renal cell carcinomaW Kimryn Rathmell, Tricia M Wright, Brian I Rini
Expert Review of Anticancer Therapy|December 9, 2016
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?Frede Donskov, Daniel Y C Heng, Brian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Clinical Pharmacokinetics|May 8, 2016
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorReza Khosravan, Robert J Motzer, Elena Fumagalli, et al.
Clinical Prostate Cancer|July 5, 2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancerGarth Beinart, Brian I Rini, Vivian Weinberg, et al.
Case Reports in Oncological Medicine|November 10, 2015
Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?Bo Zhao, Laura S Wood, Karen James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerBrian I Rini, Vivian Weinberg, Robert Bok, et al.
Pageof 41